Enric Carreras
Research Subjects
Enric Carreras has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Maribel Diaz-Ricart
Hemostasis and Erythropathology Laboratory, Hematopathology, Department of Pathology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
2 shared publications - Alexandra Martínez-Roca
Department of Hematology, Hospital Clinic Barcelona, Barcelona, Spain
1 shared publication - Alexandra Pedraza
Therapeutic Apheresis Unit, Department of Hemotherapy and Hemostasis, ICAMS, IDIBAPS, Hospital Clínic University of Barcelona Barcelona Spain
1 shared publication - Antonio Gallardo-Pizarro
Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, Barcelona, Spain. C/ Villarroel 170, Barcelona 08036, Spain
1 shared publication - Ares Guardia
Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic Barcelona, 08036 Barcelona, Spain
1 shared publication - Beatriz Merchán-Muñoz
Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic Barcelona, 08036 Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on Infectious Complications and Immune Reconstitution According to Donor Type
Background/Objectives: This study evaluated infectious complications and immune reconstitution in 253 adults undergoing peripheral blood allogeneic hematopoietic cell transplantation (allo-HCT) with post-transplant cyclophosphamide (PTCY)-based GVHD prophylaxis. Methods: Patients received grafts from HLA-matched donors (47.4%), mismatched unrelated donors (MMUD, 33.2%), or haploidentical donors (19.4%). Results: The estimated 2-year non-relapse mortality (NRM) was 11.8%, 26.4%, and 22.4%, respectively (p = 0.0528). The cumulative incidence (Cum.Inc) of acute and chronic GVHD, immunosuppression duration, and post-transplant outcomes were similar across donor types. The day +30 Cum.Inc of bacterial bloodstream infections (BSI) tended to be higher in HLA-matched transplants (49.2%, p = 0.073), while HHV-6 reactivation showed a trend toward higher frequency in haploidentical transplants (22.4%, p = 0.068). Cytomegalovirus (CMV) reactivation occurred between days +30 and +100, with the highest Cum.Inc in MMUD (59.5%, p = 0.033). BK virus-associated hemorrhagic cystitis showed a trend toward higher incidence in MMUD (22.3%, p = 0.056). Respiratory and fungal infections were most frequent in the first 100 days, with comparable rates across donor types. By day +180, most patients achieved immune reconstitution, with normalization of CD4+ T cells, CD8+ T cells, and IgG levels, independent of donor type. Conclusions: Patients undergoing allo-HCT with PTCY-based prophylaxis experience a high infectious density rate early post-transplant, which decreases after 6 months as immune reconstitution progresses, regardless of donor type.
Open AccessPost-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on Infectious Complications and Immune Reconstitution According to Donor Type
Background/Objectives: This study evaluated infectious complications and immune reconstitution in 253 adults undergoing peripheral blood allogeneic hematopoietic cell transplantation (allo-HCT) with post-transplant cyclophosphamide (PTCY)-based GVHD prophylaxis. Methods: Patients received grafts from HLA-matched donors (47.4%), mismatched unrelated donors (MMUD, 33.2%), or haploidentical donors (19.4%). Results: The estimated 2-year non-relapse mortality (NRM) was 11.8%, 26.4%, and 22.4%, respectively (p = 0.0528). The cumulative incidence (Cum.Inc) of acute and chronic GVHD, immunosuppression duration, and post-transplant outcomes were similar across donor types. The day +30 Cum.Inc of bacterial bloodstream infections (BSI) tended to be higher in HLA-matched transplants (49.2%, p = 0.073), while HHV-6 reactivation showed a trend toward higher frequency in haploidentical transplants (22.4%, p = 0.068). Cytomegalovirus (CMV) reactivation occurred between days +30 and +100, with the highest Cum.Inc in MMUD (59.5%, p = 0.033). BK virus-associated hemorrhagic cystitis showed a trend toward higher incidence in MMUD (22.3%, p = 0.056). Respiratory and fungal infections were most frequent in the first 100 days, with comparable rates across donor types. By day +180, most patients achieved immune reconstitution, with normalization of CD4+ T cells, CD8+ T cells, and IgG levels, independent of donor type. Conclusions: Patients undergoing allo-HCT with PTCY-based prophylaxis experience a high infectious density rate early post-transplant, which decreases after 6 months as immune reconstitution progresses, regardless of donor type.
- Open Access
- 11 April 2024
- Published by Springer Nature
- p. 441-458
Hepatic Complications
The frequency and severity of hepatic complications during hematopoietic cell transplantation (HCT) markedly decreased in the last decade, thanks to improvements in preventive and therapeutic measures for most frequent complications, as fungal infections, hepatotropic viruses, sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), hepatic graft-versus-host disease (GVHD), and improved management of hepatotoxic drugs and iron overload (Hockenbery et al. 2016).
- 11 April 2024
- Published by Springer Nature
- p. 441-458
Open AccessHepatic Complications
The frequency and severity of hepatic complications during hematopoietic cell transplantation (HCT) markedly decreased in the last decade, thanks to improvements in preventive and therapeutic measures for most frequent complications, as fungal infections, hepatotropic viruses, sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), hepatic graft-versus-host disease (GVHD), and improved management of hepatotoxic drugs and iron overload (Hockenbery et al. 2016).
- Open Access
- 1 April 2020
- Published by Wolters Kluwer Health in Hematology/Oncology and Stem Cell Therapy
- Vol. 13 (2) , 111-115
Is sickle cell disease-related neurotoxicity a systemic endotheliopathy?
The aim of the present article is to review the role of endothelial damage and dysfunction in the vaso-occlusive episodes associated with sickle cell disease (SCD). This inherited hematological disorder leads to irreversible damage of multiple organs through a wide variety of mechanisms, such as sickling of red cells, oxidative state due to ischemic-reperfusion episodes, inflammation, hypercoagulation state, and platelet activation, among others. In SCD, the endothelium arises as the key entity where most of these processes, which eventually lead to increased morbidly and mortality, interact. This review begins with the already accepted idea that organ-specific vasculopathy precedes clinical manifestation, and briefly explains one of the main triggers of vaso-occlusive episodes, the complex interplay between blood cells and the dysfunctional endothelium. Endothelial protective strategies emerge as a potential tool for the prevention of organ-specific disease in SCD. Actually, this knowledge is currently used for the development of potential pharmacologic interventions to improve the lives of SCD patients.
- 1 April 2020
- Published by Wolters Kluwer Health in Hematology/Oncology and Stem Cell Therapy
- Vol. 13 (2) , 111-115
Open AccessIs sickle cell disease-related neurotoxicity a systemic endotheliopathy?
The aim of the present article is to review the role of endothelial damage and dysfunction in the vaso-occlusive episodes associated with sickle cell disease (SCD). This inherited hematological disorder leads to irreversible damage of multiple organs through a wide variety of mechanisms, such as sickling of red cells, oxidative state due to ischemic-reperfusion episodes, inflammation, hypercoagulation state, and platelet activation, among others. In SCD, the endothelium arises as the key entity where most of these processes, which eventually lead to increased morbidly and mortality, interact. This review begins with the already accepted idea that organ-specific vasculopathy precedes clinical manifestation, and briefly explains one of the main triggers of vaso-occlusive episodes, the complex interplay between blood cells and the dysfunctional endothelium. Endothelial protective strategies emerge as a potential tool for the prevention of organ-specific disease in SCD. Actually, this knowledge is currently used for the development of potential pharmacologic interventions to improve the lives of SCD patients.
- Open Access
- 13 December 2018
- Published by Springer Nature
- p. 315-322
Early Complications of Endothelial Origin
- 13 December 2018
- Published by Springer Nature
- p. 315-322
Open AccessEarly Complications of Endothelial Origin
- Open Access
- 13 December 2018
- Published by Springer Nature
- p. 393-401
Noninfectious Pulmonary Complications
Lung injury occurs frequently following HSCT and significantly contributes to morbidity and mortality in the immediate post transplant period and in the months and years that follow.
- 13 December 2018
- Published by Springer Nature
- p. 393-401
Open AccessNoninfectious Pulmonary Complications
Lung injury occurs frequently following HSCT and significantly contributes to morbidity and mortality in the immediate post transplant period and in the months and years that follow.
- 17 November 2014
- Published by Wiley in British Journal of Haematology
- Vol. 168 (4) , 481-491
How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation
Summary: Sinusoidal obstruction syndrome (SOS), also called veno‐occlusive disease of the liver, is one of the most relevant complications of endothelial origin that appears early after haematopoietic cell transplantation (HCT). Despite its relatively low incidence and the fact that most cases of SOS resolve spontaneously, the cases that evolve to multi‐organ failure (MOF; severe SOS) have a mortality rate higher than 80% and represent one of the major clinical problems after HCT. For this reason, transplantation teams must have a pre‐established policy regarding preventive measures in high‐risk patients, strict daily control of weight and fluid balance during HCT, homogeneous diagnostic criteria, appropriate complementary studies for a correct differential diagnosis and measures to prevent and manage hepatorenal syndrome; in addition they must also be ready to start early treatment with defibrotide in patients with a possible severe SOS. Due to the lack of definitive evidence to enable the establishment of general recommendations in the management of SOS, this review analyses all of these aspects based on the author's personal experience.
- 17 November 2014
- Published by Wiley in British Journal of Haematology
- Vol. 168 (4) , 481-491
How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation
Summary: Sinusoidal obstruction syndrome (SOS), also called veno‐occlusive disease of the liver, is one of the most relevant complications of endothelial origin that appears early after haematopoietic cell transplantation (HCT). Despite its relatively low incidence and the fact that most cases of SOS resolve spontaneously, the cases that evolve to multi‐organ failure (MOF; severe SOS) have a mortality rate higher than 80% and represent one of the major clinical problems after HCT. For this reason, transplantation teams must have a pre‐established policy regarding preventive measures in high‐risk patients, strict daily control of weight and fluid balance during HCT, homogeneous diagnostic criteria, appropriate complementary studies for a correct differential diagnosis and measures to prevent and manage hepatorenal syndrome; in addition they must also be ready to start early treatment with defibrotide in patients with a possible severe SOS. Due to the lack of definitive evidence to enable the establishment of general recommendations in the management of SOS, this review analyses all of these aspects based on the author's personal experience.
- 30 November 2011
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 34 (9) , 635-640
Prevención y tratamiento de la enfermedad venooclusiva hepática
- 30 November 2011
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 34 (9) , 635-640
Prevención y tratamiento de la enfermedad venooclusiva hepática
- Top Cited Papers
- 4 April 2011
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (12) , 1495-1502
The role of the endothelium in the short-term complications of hematopoietic SCT
In this review, we analyse the role of the endothelium in the development of several complications that appear soon after haematopoietic SCT (HSCT). Once it had been demonstrated that sinusoidal damage is the initiating event of the sinusoidal obstruction syndrome, it was considered that other short-term complications with overlapping clinical manifestations, such as capillary leak syndrome, engraftment syndrome, transplant-associated microangiopathy, diffuse alveolar haemorrhage and idiopathic pneumonia syndrome, could have an endothelial origin. During HSCT, endothelial cells (ECs) are activated and damaged by several factors, including conditioning, cytokines released by damaged tissues, endotoxins translocated through damaged mucosa, drugs used in the procedure, the engraftment, and—in the allogeneic setting—immunological reactions. The different clinical syndromes that occur could be determined by the predominant phenotypic change in the ECs and the location of this change (organ dependant or systemic). Several translational studies have provided evidence of this endothelial dysfunction on the basis of analysis of soluble markers, soluble forms of adhesion molecules, the enumeration of circulating ECs and microparticles, and morphologic and functional changes induced in cultured ECs. This increased knowledge has opened up a wide range of potential pharmacologic interventions to prevent or treat endothelial damage and, consequently, to improve the outcome of patients receiving HSCT.
- 4 April 2011
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (12) , 1495-1502
Top Cited PapersThe role of the endothelium in the short-term complications of hematopoietic SCT
In this review, we analyse the role of the endothelium in the development of several complications that appear soon after haematopoietic SCT (HSCT). Once it had been demonstrated that sinusoidal damage is the initiating event of the sinusoidal obstruction syndrome, it was considered that other short-term complications with overlapping clinical manifestations, such as capillary leak syndrome, engraftment syndrome, transplant-associated microangiopathy, diffuse alveolar haemorrhage and idiopathic pneumonia syndrome, could have an endothelial origin. During HSCT, endothelial cells (ECs) are activated and damaged by several factors, including conditioning, cytokines released by damaged tissues, endotoxins translocated through damaged mucosa, drugs used in the procedure, the engraftment, and—in the allogeneic setting—immunological reactions. The different clinical syndromes that occur could be determined by the predominant phenotypic change in the ECs and the location of this change (organ dependant or systemic). Several translational studies have provided evidence of this endothelial dysfunction on the basis of analysis of soluble markers, soluble forms of adhesion molecules, the enumeration of circulating ECs and microparticles, and morphologic and functional changes induced in cultured ECs. This increased knowledge has opened up a wide range of potential pharmacologic interventions to prevent or treat endothelial damage and, consequently, to improve the outcome of patients receiving HSCT.
- 31 December 2010
- Published by Elsevier in Anales de Pediatría Continuada
- Vol. 8 (6) , 329-333
Preservación de la sangre de cordón umbilical
- 31 December 2010
- Published by Elsevier in Anales de Pediatría Continuada
- Vol. 8 (6) , 329-333
Preservación de la sangre de cordón umbilical